

# ERRATUM

<https://doi.org/10.29289/2594539420220036ERRATUM>

In the manuscript “Axillary surgical approach in T1-T2N0M0 clinical breast cancer staging: Survival in a women’s hospital cohort in Rio de Janeiro”, DOI: 10.29289/2594539420220036, published in the *Mastology* 2022;32:e20220036, on pages 4-5:

## Where it reads:

**Table 1.** Distribution of sociodemographic and clinicopathologic status and treatment characteristics, according to axillary approach of the cohort of 827 women with breast cancer, treated at the Brazilian National Cancer Institute (2007–2009).

	Total*	Axillary surgery n(%)		$\chi^2$	
	n (%)	SLNB	SLNB+AL <sup>a</sup>	p-value	
<b>Age</b>					
<40	54 (6.5)	41 (6.0)	13 (9.0)	0.049	
40–59	426 (51.5)	343 (50.2)	83 (57.6)		
≥60	347 (42.0)	299 (43.8)	48 (33.3)		
<b>Skin color</b>					
Non-White	267 (32.3)	229 (33.5)	38 (26.4)	0.096	
White	560 (67.7)	454 (66.5)	106 (73.6)		
<b>Marital status</b>					
With a partner	431 (52.1)	346 (50.7)	85 (59.0)	0.068	
No partner	396 (47.9)	337 (49.3)	59 (41.0)		
<b>Schooling</b>					
<8 years	350 (42.4)	296 (43.3)	54 (37.8)	0.220	
≥8 years	476 (57.6)	387 (56.7)	89(62.2)		
<b>Occupation</b>					
Unemployed	32 (3.9)	28 (4.1)	4 (2.8)	0.482	
External job	372 (45.3)	301 (44.5)	71 (49.3)		
At home	417 (50.8)	348 (51.4)	69 (47.9)		
<b>Alcoholism</b>					
No	597 (73.0)	487 (72.1)	110 (76.9)	0.243	
Yes	221 (27.0)	188 (27.9)	33 (23.1)		
<b>Smoking</b>					
No	562 (68.2)	467 (68.6)	95 (66.4)	0.617	
Yes	262 (31.8)	214 (31.4)	48 (33.6)		
<b>BMI</b>					
Low weight	35 (4.2)	30 (4.4)	5 (3.5)	0.583	
Suitable weight	227 (27.4)	193 (28.3)	34 (23.6)		
Overweight	297 (35.9)	244 (35.7)	53 (36.8)		
Obesity	268 (32.4)	216 (31.6)	52 (36.1)		
<b>Clinical staging</b>					
T1N0M0 (I)	543 (65.7)	478 (70.0)	65 (45.1)	0.000	
T2N0M0 (IIA)	284 (34.3)	205 (30.0)	79 (54.9)		
<b>Tumor size</b>					
T1	566 (68.5)	495 (72.6)	71 (49.3)	0.000	
T2	253 (30.6)	184 (27.0)	69 (47.9)		
T3	7 (0.8)	3 (0.4)	4 (2.8)		
<b>Histological type</b>					
Lobular Invasive	52 (6.3)	40 (5.9)	12 (8.3)	0.249	
Ductal Invasive	713 (86.2)	588 (86.1)	125 (86.8)		
Others	62 (7.5)	55 (8.1)	7 (4.9)		
<b>Histological grade</b>					
1	166 (22.7)	145 (24.2)	21 (16.0)	0.038	
2	293 (40.1)	243 (40.6)	50 (38.2)		
3	271 (37.1)	211 (35.2)	60 (45.8)		
<b>Number of lymph nodes removed</b>					
1–3	619 (74.8)	619 (90.6)	0 (0.0)	0.000	
4–10					
>10					
<b>Lymph node status</b>					
No metastasis	72 (8.7)	64 (9.4)	8 (5.6)		
With metastasis	136(16.4)	0 (0.0)	136 (94.4)		

Continue...

Table 1. Continuation.

	Total*	Axillary surgery n(%)		$\chi^2$
	n (%)	SLNB	SLNB+AL <sup>a</sup>	p-value
<b>Sentinel lymph node metastasis</b>				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
Micrometastasis	41 (5.0)	17 (2.5)	24 (16.7)	
Macrometastasis	87 (10.5)	0 (0.0)	87 (60.4)	
<b>Status HER2<sup>b</sup></b>				
Negative	368 (74.8)	295 (75.4)	73 (72.3)	0.366
Positive	70 (14.2)	57 (14.6)	13 (12.9)	
Indeterminate	54 (11.0)	39 (10.0)	15 (14.9)	
<b>Hormonal receptor</b>				
Positive	694 (84.7)	564 (83.6)	130 (90.3)	0.042
Negative	125 (15.3)	111 (16.4)	14 (9.7)	
<b>Triple negative<sup>b</sup></b>				
No	436 (90.8)	343 (89.8)	93 (94.9)	0.118
Yes	44 (9.2)	39 (10.2)	5 (5.1)	
<b>Other primary cancer</b>				
No	812 (98.2)	672 (98.4)	140 (97.2)	0.340
Yes	15 (1.8)	11 (1.6)	4 (2.8)	
<b>Death</b>				
No	794 (96.0)	659 (96.5)	135 (93.8)	0.127
Yes	33 (4.0)	24 (3.5)	9 (6.2)	
<b>Lymph node status</b>				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
With metastasis	128 (15.5)	17 (2.5)	111 (77.1)	
<b>Locoregional recurrence</b>				
No	808 (97.7)	665 (97.4)	143 (99.3)	0.158
Yes	19 (2.3)	18 (2.6)	1 (0.7)	
<b>Distance recurrence</b>				
No	790 (95.5)	657 (96.2)	133 (92.4)	0.043
Yes	37 (4.5)	26 (3.8)	11 (7.6)	
<b>Breast surgery</b>				
Conservative	484 (58.5)	423 (61.9)	61 (42.4)	0.000
Mastectomy	343 (41.5)	260 (38.1)	83 (57.6)	
<b>Breast reconstruction</b>				
No	681 (82.3)	557 (81.6)	124 (86.1)	0.192
Yes	146 (17.7)	126 (18.4)	20 (13.9)	
<b>Chemotherapy</b>				
No	409 (49.5)	381 (55.8)	28 (19.4)	0.000
Yes	418 (50.5)	302 (44.2)	116 (80.6)	
<b>Radiotherapy</b>				
No	328 (39.7)	265 (38.8)	63 (43.8)	0.270
Yes	499 (60.3)	418 (61.2)	81 (56.2)	
<b>Hormonal therapy</b>				
No	169 (20.4)	150 (22.0)	19 (13.2)	0.018
Yes	658 (79.6)	533 (78.0)	125 (86.8)	
<b>Target therapy</b>				
No	790 (95.5)	655 (95.9)	135 (93.8)	0.257
Yes	37 (4.5)	28 (4.1)	9 (6.2)	
<b>Severity score<sup>c</sup></b>				
0–1	78 (9.4)	78 (11.4)	0 (0.0)	0.000
2–4	675 (81.6)	573 (83.9)	102 (70.8)	
5–6	74 (8.9)	32 (4.7)	42 (29.2)	

SLNB: sentinel lymph node biopsy; AL: axillary lymphadenectomy; BMI: body mass index; HER2: human epidermal growth factor receptor 2;  $\chi^2$ : Pearson's  $\chi^2$  test; Non-white: black, brown. \*The total value may change due to missing values. <sup>a</sup>Sentinel lymph node biopsy with a subsequent axillary lymphadenectomy. <sup>b</sup>The analysis of molecular markers has become routine at Brazilian National Cancer Institute starting 2011, not all patients underwent the tests. <sup>c</sup>Severity score includes age, clinical staging, histological grade, and lymph node status.

**It should read:****Table 1.** Distribution of sociodemographic and clinicopathologic status and treatment characteristics, according to axillary approach of the cohort of 827 women with breast cancer, treated at the Brazilian National Cancer Institute (2007–2009).

	Total*	Axillary surgery N(%)		x <sup>2</sup>
	n (%)	SLNB	SLNB+AL <sup>a</sup>	p-value
<b>Age</b>				
<40	54 (6.5)	41 (6.0)	13 (9.0)	0.049
40–59	426 (51.5)	343 (50.2)	83 (57.6)	
≥60	347 (42.0)	299 (43.8)	48 (33.3)	
<b>Skin color</b>				
Non-White	267 (32.3)	229 (33.5)	38 (26.4)	0.096
White	560 (67.7)	454 (66.5)	106 (73.6)	
<b>Marital status</b>				
With a partner	431 (52.1)	346 (50.7)	85 (59.0)	0.068
No partner	396 (47.9)	337 (49.3)	59 (41.0)	
<b>Schooling</b>				
<8 years	350 (42.4)	296 (43.3)	54 (37.8)	0.220
≥8 years	476 (57.6)	387 (56.7)	89(62.2)	
<b>Occupation</b>				
Unemployed	32 (3.9)	28 (4.1)	4 (2.8)	0.482
External job	372 (45.3)	301 (44.5)	71 (49.3)	
At home	417 (50.8)	348 (51.4)	69 (47.9)	
<b>Alcoholism</b>				
No	597 (73.0)	487 (72.1)	110 (76.9)	0.243
Yes	221 (27.0)	188 (27.9)	33 (23.1)	
<b>Smoking</b>				
No	562 (68.2)	467 (68.6)	95 (66.4)	0.617
Yes	262 (31.8)	214 (31.4)	48 (33.6)	
<b>BMI</b>				
Low weight	35 (4.2)	30 (4.4)	5 (3.5)	0.583
Suitable weight	227 (27.4)	193 (28.3)	34 (23.6)	
Overweight	297 (35.9)	244 (35.7)	53 (36.8)	
Obesity	268 (32.4)	216 (31.6)	52 (36.1)	
<b>Clinical staging</b>				
T1N0M0 (I)	543 (65.7)	478 (70.0)	65 (45.1)	0.000
T2N0M0 (IIA)	284 (34.3)	205 (30.0)	79 (54.9)	
<b>Tumor size</b>				
T1	566 (68.5)	495 (72.6)	71 (49.3)	0.000
T2	253 (30.6)	184 (27.0)	69 (47.9)	
T3	7 (0.8)	3 (0.4)	4 (2.8)	
<b>Histological type</b>				
Lobular Invasive	52 (6.3)	40 (5.9)	12 (8.3)	0.249
Ductal Invasive	713 (86.2)	588 (86.1)	125 (86.8)	
Others	62 (7.5)	55 (8.1)	7 (4.9)	
<b>Histological grade</b>				
1	166 (22.7)	145 (24.2)	21 (16.0)	0.038
2	293 (40.1)	243 (40.6)	50 (38.2)	
3	271 (37.1)	211 (35.2)	60 (45.8)	
<b>Number of lymph nodes removed</b>				
1–3	619 (74.8)	619 (90.6)	0 (0.0)	0.000
4–10	72 (8.7)	64 (9.4)	8 (5.6)	
>10	136(16.4)	0 (0.0)	136 (94.4)	
<b>Sentinel lymph node metastasis</b>				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
Micrometastasis	41 (5.0)	17 (2.5)	24 (16.7)	
Macrometastasis	87 (10.5)	0 (0.0)	87 (60.4)	

Continue...

Table 1. Continuation.

	Total*	Axillary surgery N(%)		x <sup>2</sup>
	n (%)	SLNB	SLNB+AL <sup>a</sup>	p-value
<b>Status HER2<sup>b</sup></b>				
Negative	368 (74.8)	295 (75.4)	73 (72.3)	0.366
Positive	70 (14.2)	57 (14.6)	13 (12.9)	
Indeterminate	54 (11.0)	39 (10.0)	15 (14.9)	
<b>Hormonal receptor</b>				
Positive	694 (84.7)	564 (83.6)	130 (90.3)	0.042
Negative	125 (15.3)	111 (16.4)	14 (9.7)	
<b>Triple negative<sup>b</sup></b>				
No	436 (90.8)	343 (89.8)	93 (94.9)	0.118
Yes	44 (9.2)	39 (10.2)	5 (5.1)	
<b>Other primary cancer</b>				
No	812 (98.2)	672 (98.4)	140 (97.2)	0.340
Yes	15 (1.8)	11 (1.6)	4 (2.8)	
<b>Death</b>				
No	794 (96.0)	659 (96.5)	135 (93.8)	0.127
Yes	33 (4.0)	24 (3.5)	9 (6.2)	
<b>Lymph node statu</b>				
No metastasis	699 (84.5)	666 (97.5)	33 (22.9)	0.000
With metastasis	128(15.5)	17 (2.5)	111 (77.1)	
<b>Locoregional recurrence</b>				
No	808 (97.7)	665 (97.4)	143 (99.3)	0.158
Yes	19 (2.3)	18 (2.6)	1 (0.7)	
<b>Distance recurrence</b>				
No	790 (95.5)	657 (96.2)	133 (92.4)	0.043
Yes	37 (4.5)	26 (3.8)	11 (7.6)	
<b>Breast surgery</b>				
Conservative	484 (58.5)	423 (61.9)	61 (42.4)	0.000
Mastectomy	343 (41.5)	260 (38.1)	83 (57.6)	
<b>Breast reconstruction</b>				
No	681 (82.3)	557 (81.6)	124 (86.1)	0.192
Yes	146 (17.7)	126 (18.4)	20 (13.9)	
<b>Chemotherapy</b>				
No	409 (49.5)	381 (55.8)	28 (19.4)	0.000
Yes	418 (50.5)	302 (44.2)	116 (80.6)	
<b>Radiotherapy</b>				
No	328 (39.7)	265 (38.8)	63 (43.8)	0.270
Yes	499 (60.3)	418 (61.2)	81 (56.2)	
<b>Hormonal therapy</b>				
No	169 (20.4)	150 (22.0)	19 (13.2)	0.018
Yes	658 (79.6)	533 (78.0)	125 (86.8)	
<b>Target therapy</b>				
No	790 (95.5)	655 (95.9)	135 (93.8)	0.257
Yes	37 (4.5)	28 (4.1)	9 (6.2)	
<b>Severity score<sup>c</sup></b>				
0–1	78 (9.4)	78 (11.4)	0 (0.0)	0.000
2–4	675 (81.6)	573 (83.9)	102 (70.8)	
5–6	74 (8.9)	32 (4.7)	42 (29.2)	

SLNB: sentinel lymph node biopsy; AL: axillary lymphadenectomy; BMI: body mass index; HER2: human epidermal growth factor receptor 2; x<sup>2</sup>: Pearson's x<sup>2</sup> test; Non-white: black, brown. \*The total value may change due to missing values. <sup>a</sup>Sentinel lymph node biopsy with a subsequent axillary lymphadenectomy. <sup>b</sup>The analysis of molecular markers has become routine at Brazilian National Cancer Institute starting 2011, not all patients underwent the tests. <sup>c</sup>Severity score includes age, clinical staging, histological grade, and lymph node status.

